Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18590312 | RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18473720 | Mutated Glycoprotein of Vesicular Stomatitis Virus | September 2023 | February 2024 | Allow | 5 | 0 | 0 | No | No |
| 18464786 | PREFUSION RSV F PROTEINS AND THEIR USE | September 2023 | December 2023 | Allow | 3 | 0 | 0 | No | No |
| 18335879 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | June 2023 | June 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18335869 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | June 2023 | April 2024 | Allow | 10 | 0 | 0 | No | No |
| 18335876 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | June 2023 | April 2024 | Allow | 10 | 0 | 0 | No | No |
| 18308583 | PRE-FUSION RSV F ANTIGENS | April 2023 | March 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18173006 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | February 2023 | September 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18058185 | SYSTEMS AND METHODS FOR THE PREPARATION OF VACCINES UTILIZING PREDICTABLY INACTIVATED PATHOGENS | November 2022 | February 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 17821694 | STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES | August 2022 | October 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17800296 | SYSTEMS AND METHODS FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES | August 2022 | February 2024 | Allow | 18 | 3 | 0 | Yes | No |
| 17883833 | RAPID DETECTION TEST FOR SARS-COV-2 | August 2022 | August 2023 | Allow | 19 | 1 | 1 | No | No |
| 17861189 | VACCINES AGAINST HEPATITIS B VIRUS | July 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17857534 | Oncolytic Poliovirus for Human Tumors | July 2022 | August 2023 | Allow | 13 | 1 | 0 | No | No |
| 17848205 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | June 2022 | February 2023 | Allow | 8 | 2 | 0 | No | No |
| 17848176 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | June 2022 | February 2023 | Allow | 8 | 2 | 0 | No | No |
| 17750470 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY | May 2022 | May 2023 | Allow | 12 | 1 | 0 | No | No |
| 17664290 | VACCINE AGAINST RSV | May 2022 | July 2023 | Allow | 14 | 1 | 0 | No | No |
| 17715741 | PHARMACEUTICAL AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SARS-COV-2 | April 2022 | February 2023 | Abandon | 10 | 1 | 0 | No | No |
| 17681206 | PREVENTION OF VIRAL TRANSMISSION BY NAKED GENETIC MATERIAL | February 2022 | March 2023 | Allow | 13 | 2 | 0 | Yes | No |
| 17677399 | METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) | February 2022 | July 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17636469 | SALIVA-BASED MOLECULAR TESTING FOR SARS-COV-2 | February 2022 | August 2022 | Allow | 6 | 0 | 0 | No | No |
| 17668287 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | February 2022 | November 2023 | Allow | 21 | 1 | 0 | No | No |
| 17592333 | NEWCASTLE DISEASE VIRUS-BASED VECTORED VACCINE | February 2022 | September 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17585981 | ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE | January 2022 | June 2024 | Allow | 28 | 2 | 1 | No | No |
| 17579879 | METHOD FOR THE SAFE INDUCTION OF IMMUNITY AGAINST RSV | January 2022 | May 2023 | Allow | 16 | 1 | 0 | No | No |
| 17577704 | METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST RSV INFECTION | January 2022 | May 2023 | Allow | 16 | 1 | 0 | No | No |
| 17564962 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | December 2021 | September 2023 | Allow | 21 | 1 | 0 | Yes | No |
| 17556413 | SARS-COV-2 VIRUSES AND METHODS OF USE THEREOF | December 2021 | July 2022 | Allow | 7 | 1 | 0 | No | No |
| 17544293 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | December 2021 | May 2023 | Allow | 17 | 1 | 0 | No | No |
| 17525775 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | November 2021 | August 2023 | Allow | 21 | 4 | 1 | Yes | No |
| 17524380 | PREFUSION RSV F PROTEINS AND THEIR USE | November 2021 | September 2023 | Allow | 22 | 0 | 1 | Yes | No |
| 17451955 | RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF | October 2021 | January 2023 | Allow | 15 | 0 | 0 | No | No |
| 17502785 | METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE | October 2021 | June 2023 | Allow | 20 | 1 | 0 | No | No |
| 17499495 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | October 2021 | June 2023 | Allow | 20 | 1 | 0 | No | No |
| 17485705 | INFLUENZA HEMAGGLUTININ PROTEINS AND METHODS OF USE THEREOF | September 2021 | June 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17478533 | PREFUSION RSV F PROTEINS AND THEIR USE | September 2021 | August 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17473972 | AVIAN INFLUENZA AND FOWL ADENOVIRUS TYPE 4 BI-COMBINED GENETIC ENGINEERING SUBUNIT VACCINE AND METHOD FOR PREPARING THE SAME | September 2021 | February 2022 | Allow | 6 | 0 | 0 | No | No |
| 17393328 | Peptides for Covid-19 Prevention and Treatment | August 2021 | February 2024 | Allow | 31 | 2 | 0 | No | No |
| 17332901 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | May 2021 | January 2024 | Allow | 32 | 1 | 0 | No | No |
| 17314649 | PRE-FUSION RSV F ANTIGENS | May 2021 | June 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17226690 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | April 2021 | October 2021 | Allow | 6 | 1 | 0 | No | No |
| 17210409 | ENGINEERING OF DENDRITIC CELLS FOR GENERATION OF VACCINES AGAINST SARS-COV-2 | March 2021 | May 2022 | Abandon | 13 | 1 | 1 | No | No |
| 17196846 | IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF PRODUCTION FOR CORONAVIRUS | March 2021 | May 2022 | Abandon | 14 | 1 | 1 | No | No |
| 17173617 | MOUSE-ADAPTED SARS-COV-2 VIRUSES AND METHODS OF USE THEREOF | February 2021 | November 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 17170876 | Composition and Method of mRNA Vaccines Against Novel Coronavirus Infection | February 2021 | February 2024 | Allow | 36 | 1 | 1 | No | No |
| 17265267 | INTRANASAL VACCINE THAT INDUCES CELLULAR IMMUNITY | February 2021 | October 2022 | Allow | 21 | 1 | 0 | No | No |
| 17155953 | VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE | January 2021 | June 2022 | Abandon | 17 | 3 | 0 | No | No |
| 17262263 | ATTENUATED VIRUS STRAIN AND USE THEREOF AS A VACCINE | January 2021 | August 2022 | Allow | 18 | 1 | 0 | Yes | No |
| 17261828 | NIPAH VIRUS IMMUNOGENS AND THEIR USE | January 2021 | September 2023 | Allow | 32 | 0 | 1 | Yes | No |
| 17140383 | Test Kit For Detecting A Plurality Of Analytes | January 2021 | May 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17126128 | Stabilized Soluble Pre-Fusion RSV F Polypeptides | December 2020 | September 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17080224 | COLD-ADAPTED LIVE ATTENUATED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS AND VACCINE CONTAINING THE SAME | October 2020 | March 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 17078704 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | October 2020 | March 2023 | Abandon | 29 | 2 | 0 | No | No |
| 17049916 | CHIMERIC VECTORS | October 2020 | April 2024 | Allow | 42 | 2 | 1 | No | No |
| 17070664 | RECOMBINANT TURKEY HERPESVIRUS VACCINES AND USES THEREOF | October 2020 | April 2022 | Allow | 18 | 1 | 0 | No | No |
| 17065514 | Peptides for Covid-19 Prevention and Treatment | October 2020 | May 2021 | Allow | 7 | 1 | 0 | Yes | No |
| 17061136 | Ferritin Proteins | October 2020 | November 2023 | Allow | 37 | 1 | 1 | No | No |
| 17028288 | METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) | September 2020 | June 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17025568 | RECOMBINANT RSV WITH SILENT MUTATIONS, VACCINES, AND METHODS RELATED THERETO | September 2020 | June 2022 | Allow | 21 | 1 | 0 | No | No |
| 17025110 | TREATMENTS TO ELIMINATE HIV RESERVOIRS AND REDUCE VIRAL LOAD | September 2020 | November 2022 | Abandon | 26 | 2 | 0 | No | No |
| 16981439 | COMPOSITIONS AND METHODS FOR VACCINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION | September 2020 | November 2022 | Allow | 26 | 2 | 0 | Yes | No |
| 17016699 | Oncolytic Poliovirus for Human Tumors | September 2020 | March 2022 | Allow | 18 | 1 | 0 | No | No |
| 17015905 | VACCINE COMPOSITION | September 2020 | May 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16977327 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | September 2020 | December 2022 | Allow | 27 | 1 | 1 | No | No |
| 16971020 | ANTI-VIRAL PROTEINS | August 2020 | March 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16941394 | ANTIBODIES THAT POTENTLY NEUTRALIZE RSV AND USES THEREOF | July 2020 | February 2022 | Allow | 19 | 1 | 0 | No | No |
| 16964118 | STABILIZED RSV F PROTEINS AND USES THEREOF | July 2020 | September 2022 | Allow | 26 | 1 | 0 | No | No |
| 16920089 | MAMMARY TUMOR VIRUS SUPPRESSION | July 2020 | May 2024 | Allow | 46 | 5 | 1 | Yes | Yes |
| 16946485 | VACCINE AGAINST RSV | June 2020 | January 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 16901993 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY | June 2020 | January 2022 | Allow | 19 | 1 | 0 | No | No |
| 16893706 | STABILIZED LIQUID LIVE VACCINE | June 2020 | May 2023 | Allow | 35 | 3 | 0 | Yes | No |
| 16892132 | METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES | June 2020 | August 2021 | Allow | 15 | 1 | 1 | No | No |
| 16885009 | ANTIBODIES THAT NEUTRALIZE RSV, MPV AND PVM AND USES THEREOF | May 2020 | April 2022 | Allow | 22 | 1 | 0 | No | No |
| 15931654 | SUPERHUMAN ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF | May 2020 | February 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 15931649 | ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM CR3022 | May 2020 | February 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 15931643 | ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 2GHW | May 2020 | February 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 16763497 | RECOMBINANT RSV G PROTEINS AND THEIR USE | May 2020 | October 2023 | Allow | 41 | 1 | 1 | No | No |
| 16864454 | RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF | May 2020 | April 2021 | Allow | 11 | 2 | 0 | No | No |
| 16760565 | ADENOVIRUS VECTORS AND USES THEREOF | April 2020 | June 2022 | Allow | 25 | 0 | 0 | No | No |
| 16646363 | METHOD FOR DETECTING ACUTE BORNA DISEASE VIRUS (BDV) INFECTIONS, AND DIAGNOSTIC KIT THEREFOR, IN PARTICULAR IN COMBINATION WITH METHODS FOR DISTINGUISHING ACUTE FROM CHRONIC AND LATENT BDV INFECTIONS, AND DIAGNOSTIC KITS THEREFOR | April 2020 | July 2023 | Allow | 40 | 2 | 0 | Yes | No |
| 16755805 | BIOSENSOR FOR DETECTING INFLUENZA A VIRUS USING AU-FE3O4 COMPOSITE | April 2020 | September 2022 | Allow | 29 | 1 | 0 | No | No |
| 16845930 | METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE | April 2020 | January 2022 | Abandon | 22 | 2 | 0 | Yes | No |
| 16649271 | Mutated Glycoprotein of Vesicular Stomatitis Virus | March 2020 | June 2024 | Allow | 51 | 2 | 2 | No | No |
| 16647758 | VACCINES AND METHODS OF MAKING AND USING VACCINES FOR PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | March 2020 | April 2024 | Abandon | 49 | 4 | 0 | Yes | No |
| 16801696 | COMPOSITIONS AND METHODS FOR TREATMENT IN BROAD-SPECTRUM, UNDIFFERENTIATED OR MIXED CLINICAL APPLICATIONS | February 2020 | May 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16642082 | METHOD FOR THE SAFE INDUCTION OF IMMUNITY AGAINST RSV | February 2020 | September 2021 | Allow | 18 | 1 | 0 | No | No |
| 16786954 | TREATMENT OF HUMAN METAPNEUMOVIRUS | February 2020 | January 2022 | Abandon | 24 | 2 | 0 | No | Yes |
| 16638072 | DIFFERENTIAL COATING OF MICROPROJECTIONS AND MICRONEEDLES ON ARRAYS | February 2020 | August 2023 | Abandon | 42 | 2 | 0 | No | Yes |
| 16637155 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | February 2020 | October 2021 | Allow | 20 | 0 | 0 | Yes | No |
| 16752328 | COMBINATION OF IMMUNO-ONCOLYTIC VIRUS DRUGS FOR ENHANCING SYSTEMIC IMMUNE RESPONSE AND APPLICATION THEREOF | January 2020 | March 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16742036 | ANTIBODY, COMPOSITE, DETECTION DEVICE AND METHOD USING SAME | January 2020 | November 2021 | Allow | 22 | 1 | 0 | No | No |
| 16739890 | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS | January 2020 | December 2021 | Abandon | 23 | 2 | 0 | No | No |
| 16630421 | METHOD FOR PRESERVING BIOPHARMACEUTICALS | January 2020 | April 2022 | Allow | 27 | 0 | 1 | No | No |
| 16730429 | VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALS | December 2019 | June 2021 | Allow | 18 | 2 | 0 | No | No |
| 16721229 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | December 2019 | December 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16620829 | METHOD FOR EVALUATING SEVERITY OF DENGUE VIRUS INFECTION IN INDIVIDUAL, DETECTION DEVICE AND DETECTION | December 2019 | September 2023 | Abandon | 45 | 3 | 0 | No | No |
| 16696943 | RECOMBINANT TURKEY HERPESVIRUS VACCINES AND USES THEREOF | November 2019 | June 2020 | Allow | 7 | 1 | 0 | No | No |
| 16616876 | NANOSTRUCTURE WITH A NUCLEIC ACID SCAFFOLD AND VIRUS-BINDING PEPTIDE MOIETIES | November 2019 | October 2023 | Abandon | 46 | 4 | 0 | No | No |
| 16615372 | SIMULTANEOUS IN VITRO ANALYSIS OF VACCINE POTENCY AND TOXIN CONCENTRATION | November 2019 | July 2023 | Abandon | 44 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HILL, MYRON G.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HILL, MYRON G works in Art Unit 1648 and has examined 682 patent applications in our dataset. With an allowance rate of 53.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner HILL, MYRON G's allowance rate of 53.1% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HILL, MYRON G receive 2.10 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HILL, MYRON G is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +30.7% benefit to allowance rate for applications examined by HILL, MYRON G. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 44.9% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 79.4% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 56.7% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.7% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.8% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.